Cargando…

Anti-angiogenic effect of the combination of low-dose sorafenib and EGCG in HCC-induced Wistar rats

Background: Sorafenib is a standard drug used for advanced hepatocellular carcinoma but is often resistant and toxic. Its combination with epigallo-3-catechin gallate leads to reduced resistance and toxicity but an equally effective anti-angiogenic effect.Therefore, this study aims to assess the an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Irawan, Andry, Prabowo, Erik, Riwanto, Ignatius, Atmodjo, Wahyuni Lukita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843086/ https://www.ncbi.nlm.nih.gov/pubmed/36726605 http://dx.doi.org/10.12688/f1000research.109142.3

Ejemplares similares

Characterization of alpha-fetoprotein effects on dendritic cell and its function as effector immune response activator
por: Suryatenggara, Jeremiah, et al.
Publicado: (2017)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
por: Guo, Lingling, et al.
Publicado: (2023)

GHR knockdown enhances the sensitivity of HCC cells to sorafenib
por: Gao, Shuang, et al.
Publicado: (2020)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4
por: He, Xi, et al.
Publicado: (2021)

Anti-bacterial Activities of EGCG Nanoparticles
por: Fan, Baochan, et al.
Publicado: (2022)

The Effects of Phyllanthus niruri Linn on Infiltrating Dendritic Cell and Ratio of Neutrophile/Lymphocytes in Chemotherapy of Sprague-Dawley Rats with Colorectal Cancer
por: Tendean, Michael, et al.
Publicado: (2021)

The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance
por: Chow, Ariel Ka-Man, et al.
Publicado: (2013)

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
por: Palmer, D H, et al.
Publicado: (2013)

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
por: De Matteis, Serena, et al.
Publicado: (2021)

Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
por: Shrestha, Ritu, et al.
Publicado: (2021)

A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo
por: Xu, Yu-Yin, et al.
Publicado: (2013)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
por: Lei, Jin, et al.
Publicado: (2022)

Investigations on the dose–response relationship of combined exposure to low doses of three anti-androgens in Wistar rats
por: Schneider, Steffen, et al.
Publicado: (2017)

Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC
por: Hajighasemlou, Saieh, et al.
Publicado: (2020)

Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
por: Fornari, Francesca, et al.
Publicado: (2021)

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
por: Yuen, J S P, et al.
Publicado: (2011)

Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS)
por: Han, Sojung, et al.
Publicado: (2022)

Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation
por: Lai, Hong-Yue, et al.
Publicado: (2021)

Validation of a Lab-on-Chip Assay for Measuring Sorafenib Effectiveness on HCC Cell Proliferation
por: Piccinno, Emanuele, et al.
Publicado: (2021)

Anti-angiogenic effect of high doses of ascorbic acid
por: Mikirova, Nina A, et al.
Publicado: (2008)

Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study
por: Yao, Qi, et al.
Publicado: (2017)

Comparative analysis of tumor-associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: A retrospective study
por: Chen, Ligang, et al.
Publicado: (2018)

Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
por: D’Alessandro, Rosalba, et al.
Publicado: (2019)

Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies
por: Li, Huichen, et al.
Publicado: (2020)

Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo
por: Xu, Yu-Yin, et al.
Publicado: (2023)

Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1–7)
por: Abd-Alhaseeb, Mohammad M., et al.
Publicado: (2014)

Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
por: Assenat, Eric, et al.
Publicado: (2019)

Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients
por: Feng, Yu-Min, et al.
Publicado: (2015)

LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription
por: Lin, Zhongjie, et al.
Publicado: (2020)

A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC
por: Liu, Xiang, et al.
Publicado: (2022)

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial
por: Seidensticker, Max, et al.
Publicado: (2023)

Anti-Arthritic and Anti-Inflammatory Effects of Andaliman Extract and Nanoandaliman in Inflammatory Arthritic Mice
por: Setiadi, Anselmus Yakobus Lukita Adiandra, et al.
Publicado: (2022)

Epigallocatechin Gallate (EGCG) Improves Anti-Angiogenic State, Cell Viability, and Hypoxia-Induced Endothelial Dysfunction by Downregulating High Mobility Group Box 1 (HMGB1) in Preeclampsia
por: Zhong, Min, et al.
Publicado: (2020)

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
por: Ciciola, Paola, et al.
Publicado: (2020)

The Environment Is a Key Factor in Determining the Anti-Amyloid Efficacy of EGCG
por: Sneideris, Tomas, et al.
Publicado: (2019)

Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro
por: Qu, Zhen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ks3o8q1voiir6fp6bvvu73dr2i